Clinical Trial Update: N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating N-acetylcysteine for renal protection in patients with rheumatic heart disease undergoing valve replacement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Rheumatic Heart Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Assiut University | Conditions: Cardiac Surgery for Rheumatic Valvular Heart Disease, Renal Dysfunction | Phase 2 | Status: COMPLETED